Free Trial
NYSE:ARA

American Renal Associates (ARA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$11.33
$11.52
50-Day Range
$11.46
$11.52
52-Week Range
$5.57
$11.98
Volume
9,831 shs
Average Volume
106,940 shs
Market Capitalization
$397.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ARA stock logo

About American Renal Associates Stock (NYSE:ARA)

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

ARA Stock News Headlines

See More Headlines
Receive ARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2020
Today
5/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Fax
N/A
Employees
4,977
Year Founded
N/A

Profitability

Net Income
$-13,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$822.52 million
Cash Flow
$1.69 per share
Book Value
$2.59 per share

Miscellaneous

Free Float
N/A
Market Cap
$397.94 million
Optionable
Optionable
Beta
1.11
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joseph A. Carlucci (Age 66)
    Co-Founder, CEO & Chairman
    Comp: $1.06M
  • Mr. Syed T. Kamal (Age 67)
    Co-Founder, Pres & Director
    Comp: $947.14k
  • Dr. Don E. Williamson (Age 58)
    Exec. VP & COO
    Comp: $1.22M
  • Mr. Mark C. Herbers (Age 65)
    Interim CFO & Interim Chief Accounting Officer
  • Mr. Richard Pacheco CFE
    AVA, MBA, VP of Admin.
  • Mr. Neal Minahan
    Chief Compliance Officer & VP
  • Ms. Victoria A. Labriola Esq.
    M.B.A., VP, Gen. Counsel & Sec.
  • Ms. Jennifer Hood
    VP of HR
  • Dr. Richard Cronin M.D.
    Chief Medical Officer
  • Ms. Shari Cousins R.N.
    C.N.N., Sr. VP of Clinical & Regulatory Services

ARA Stock Analysis - Frequently Asked Questions

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings, Inc. (NYSE:ARA) released its quarterly earnings results on Wednesday, November, 11th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.09. The company earned $209.69 million during the quarter, compared to analysts' expectations of $211.50 million. American Renal Associates had a negative trailing twelve-month return on equity of 3.56% and a negative net margin of 2.04%.

What is Joseph Carlucci's approval rating as American Renal Associates' CEO?

62 employees have rated American Renal Associates Chief Executive Officer Joseph Carlucci on Glassdoor.com. Joseph Carlucci has an approval rating of 57% among the company's employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Zevra Therapeutics (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA).

When did American Renal Associates IPO?

American Renal Associates (ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

This page (NYSE:ARA) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners